Replicel Planning New Hair Loss Study In Europe
Yesterday, Replicel released a May 2019 Update which mentioned a new study using its dermal injector device to treat hair loss.
The end of the press release states:
“Over the next 18 months you should expect to see:
- new clinical data from a study completed showing the value of the dermal injector in treating hair loss, and
- clinical data from the Shiseido-funded study of our hair loss treatment (RCH-01) in Japan with clarity around its intentions to launch the product.”
RCI-02 Dermal Injector Prototype (CNW Group/RepliCel Life Sciences Inc.)
This indicates that the above mentioned study using the dermal injector in treating hair loss is separate from Shiseido’s study. This was the first time I’ve heard of the study using the dermal injector for hair loss so I decided to reach out to Replicel CEO Lee Buckler to get more information on it. He responded to me via a tweet below:
We have not yet conducted the study. We are waiting for the commercial-grade prototypes. The study is designed and will be conducted in Europe. The substance and indication have not yet been made public.
— Lee Buckler (@celltherapy) May 21, 2019
Still To Come
Lee specifically mentions in the tweet that the substance and indication have not yet been made public. This is interesting because it alludes to the fact that Replicel may be trying a new substance other than RCH-01 in this study for the treatment of hair loss. The indication (or disease type) would still presumably be some form of androgenic alopecia, and for some reason my guess is the study could be targeting females. Good to hear news about a new trial coming from Replicel.
Posted in Hair Growth Treatment, Replicel
Am I to understand that nothing of commercial use will come from either company in 2019?
Perhaps the second study is due to failed or less than desirable results the first time?
It still sounds like Shiseido will be out in 2019.
@Follice Thought Out in 2019? Sounds great. Let’s look out for those results to se if it’s a 20, 50, 90, or 100 percent cure. According to your timeline, when do you think Dr. Tsuji’s treatment will release? Hairlosscure2020 says their on track for next year. Your thoughts?
It’s hard to say because you never know, I would be surprised if they were on track for next year but it’s possible.
Understood. But you think Shiseido could release this year?
Who is Dr. Tsuji? Does he have anything to do with Replicel?
Thanks for responding however, I am still confused as to what it is Shisedio will release in 2019? Is the dermal injector above for in home use? Only commercial use?
Dermal injector is for clinical use. Most likely Shiseido will begin a release of RCH-01 treatments in Japan.
Agreed, Replicel was supposed to have already started this study in Europe if memory serves correct.
Anything can happen but it sure sounds like that Shiseido email that circulated the internet about a July announcement sure could be the news of an RCH-01 product launch.
Competition brings out the best in people. It’ll be huge to actually get a product in the market that works! A solution to a problem man-kind has never really solved might be on the doorstep.
In Germany and the world, men get infertility and other diseases related to post-Finasteride syndrome .
Elaf of Berlin, the drug Finasteride, who suffered infertility, prompting him to sue the pharmaceutical company “Dermaphram”.
The court issued a warning letter to all men who may resort to phentermide-containing drugs for hair development, especially since the Federal Institute for Drug Control and Medicines warned in July 2018 of the risks of drugs containing Finasteride, and reported in a report that it caused sexual and psychological disorders.
The complainant stated that he had become almost sterile, suffered from permanent depression, and suffered severe pain from time to time in the pubic, although he stopped the use of the drug 5 years ago. So the young man demands the company “Dirmaphram” for 100 thousand euros in compensation for the losses suffered by genital and psychological.
Frank mentioned that he was in good health and did not mention that he visited the doctor much before. He confirmed that his health problems began in 2010 after spending 5 years in the use of Finasteride. And from her day he suffers from depression, sexual disorder and pain in the head and abdomen.
In the United States, more than 1,400 men have sued Merck,
so it means rch-01 will be made available commercially in 2019?
if yes, when approximately
It seems like a 2019 release but we can’t be sure yet.
Hi Follicle Thought, Replicel has tweeted yesterday that Shiseido has shared data from their clinical trials, but the tweet is a bit ambigious and the data from the clinical trial is in Japanese, if you have read the tweet does this mean that Shiseido and Replicel would continue their partnership and do you think a member of the forum would be able to translate the results of the clinical trial?
The tweet doesn’t mention anything specific about the partnership or arbitration. The clinical trial record was updated, but this does not mean that data was shared.